

LISTING AND AMENDMENT OF THE CLAIMS:

1. (Currently amended) A soft gelatin capsule containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form ~~or a pharmacologically acceptable derivative thereof~~ characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source.
2. (Original) A soft gelatin capsule as claimed in Claim 1 wherein formulation comprises 5, 8, 11, 14, 17-eicosapentaenoic acid (or "EPA").
3. (Original) A soft gelatin capsule as claimed in Claim 2 wherein EPA is present in an amount of at least about 50 wt % of the formulation.
4. (Original) A soft gelatin capsule as claimed in Claim 2 or Claim 3 wherein EPA is present in an amount of between from about 50 wt % to about 60 wt % of the formulation.
5. (Original) A soft gelatin capsule as claimed in Claim 2 or Claim 3 wherein EPA is present in an amount of at least about 90 wt % of the formulation.
6. (Currently amended) A soft gelatin capsule as claimed in any one of the ~~preceding claims~~ Claims 1, 2 or 3 wherein the formulation comprises 4, 7, 10, 13, 16, 19-docosahexaenoic acid (or "DHA").
7. (Currently amended) A soft gelatin capsule as claimed in Claim 6 ~~insofar as dependent from any of Claims 1 to 4~~ wherein DHA is present in an amount of between from about 20 wt % to about 30 wt % of the formulation.

Serial Number: TBA  
Attorney Docket: SACH3001/ESS

8. (Currently amended) A soft gelatin capsule as claimed in any one of the ~~preceding claims~~ Claims 1, 2 or 3 comprising between from about 100mg to about 2000mg of said formulation.
9. (Currently amended) A soft gelatin capsule as claimed in ~~any of the preceding claims~~ Claim 8 comprising about 500mg of said formulation.
10. (Currently amended) A soft gelatin capsule as claimed in ~~any of Claims 1 to~~ Claim 8 comprising about 1000mg of said formulation.
11. (Canceled)
12. (Canceled)
13. (Currently amended) A soft gelatin capsule as claimed in any one of the ~~preceding claims~~ Claims 1, 2 or 3 wherein the gelatin comprises porcine gelatin.
14. (Currently amended) A soft gelatin capsule as claimed in any one of ~~Claims 1 to 42~~ Claims 1, 2 or 3 wherein the gelatin comprises bovine gelatin.
15. (Currently amended) A soft gelatin capsule as claimed in any one of ~~Claims 1 to 42~~ Claims 1, 2 or 3 wherein the gelatin comprises fish gelatin.
16. (Currently amended) A soft gelatin capsule as claimed in ~~any of the preceding claims~~ Claim 1 wherein the wall of the capsule consists of a single layer.
17. (Currently amended) A soft gelatin capsule as claimed in ~~any of the preceding claims~~ Claim 1 wherein the capsule delays release of the formulation until after passage through the stomach.

Serial Number: TBA  
Attorney Docket: SACH3001/ESS

18. (Currently amended) A soft gelatin capsule as claimed in ~~any of the preceding claims~~ Claim 1 wherein the capsule delays release of the formulation until after passage beyond the pancreatic duct in the duodenum.

19. (Original) A soft gelatin capsule as claimed in Claim 17 or Claim 18 wherein the capsule is coated with at least one enteric material.

20. (Currently amended) A soft gelatin capsule as claimed in ~~any of Claims 17 to Claim 19~~ Claim 19 wherein at least one enteric material is integrated within the gelatin of the capsule.

21. (Currently amended) A soft gelatin capsule as claimed in Claim 19 ~~or Claim 20~~ wherein the or at least one enteric material is a neutral polyacrylate polymer.

22. (Currently amended) A soft gelatin capsule as claimed in ~~any of Claims 19 to 24~~ Claim 20 wherein the or at least one enteric material is poly(ethylacrylate-methylmethacrylate).

23. (Canceled)

24. (Canceled)

25. (Currently amended) A process for the manufacture of a soft gelatin capsule containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form ~~or a pharmacologically acceptable derivative thereof~~, said process comprising encapsulating said pharmaceutical formulation in gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source.

26. (Canceled)

27. (Canceled)

28. (Canceled)

29. (Canceled)

30. (Currently amended) A method of treatment or prophylaxis of a condition selected from chronic inflammatory conditions, hyperlipidaemia, hypertriglyceridaemia, asthma, bipolar disorder and neoplastic disease comprising administering a therapeutically effective amount of a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form ~~or a pharmaceutically acceptable salt thereof per day~~ in the form of a plurality of soft gelatin capsules ~~as defined in Claim 4~~ containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form characterized in that the capsule comprises gelatine extracted by an extraction process comprising acid pre-treatment of a collagen source.

31. (Currently amended) A method as claimed in Claim 30 wherein the soft gelatin capsules ~~are as defined in any of Claims 2 to 22~~ wherein the omega-3 polyunsaturated fatty acid in free acid form comprises EPA.

32. (Canceled)

33. (Canceled)

34. (Canceled)